Media Summary: Gina Columbus reports on FDA approvals in cutaneous squamous cell carcinoma, non–small cell lung cancer, and multiple ... Data and practical implications are reviewed from the phase 2 EMPOWER- Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and ...

Breakthrough Therapy Designation In Cscc - Detailed Analysis & Overview

Gina Columbus reports on FDA approvals in cutaneous squamous cell carcinoma, non–small cell lung cancer, and multiple ... Data and practical implications are reviewed from the phase 2 EMPOWER- Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and ... George R. Simon, MD, reports on an FDA approval in bladder cancer, a Stay informed with the latest immunology breakthroughs, FDA approvals, and clinical trial updates. In this episode, we highlight ... Gina Columbus reports on FDA approvals in large B-cell lymphoma and melanoma, priority review

Gina Columbus reports on FDA approvals in graft-versus-host disease, colorectal cancer, and acute myeloid leukemia, a priority ... Key opinion leaders provide some closing thoughts vis-à-vis the Gina Columbus reports on FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, ... Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer. Phio's core ... Watch our leading specialists as they discuss the role of the multidisciplinary team in the care of patients with cutaneous ... In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising ...

At USC Norris Comprehensive Cancer Center, researchers collaborate with top scientists across disciplines and across USC's ... This session introduces the Inpatient Prospective Payment System (IPPS) and explains how inpatient data is used to determine ... The COVID-19 pandemic created widespread disruptions in clinical care and education. As the pandemic receded, educational ...

Photo Gallery

Breakthrough Therapy Designation in CSCC, 2017 ESMO Congress Highlights, and More
FDA Approvals in CSCC, NSCLC, and Myeloma, Breakthrough Designation in Prostate Cancer, and More
Advanced CSCC: The New Systemic Therapy
Applying the breakthrough therapy criteria: Oncology
Dr. Pazdur on the Requirements for a Breakthrough Therapy Designation
FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More
Immunology Update – October 22, 2025: Etrasimod UC, Upadacitinib Approval, Pediatric SIMPONI & More
FDA Approvals in Large B-Cell Lymphoma and Melanoma, Priority Reviews in CSCC and NSCLC, and More
FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More
Advice for the Management of CSCC
FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More
Force Webinar: Phio Pharma, 5 February 2026
View Detailed Profile
Breakthrough Therapy Designation in CSCC, 2017 ESMO Congress Highlights, and More

Breakthrough Therapy Designation in CSCC, 2017 ESMO Congress Highlights, and More

Gina Columbus reports on a

FDA Approvals in CSCC, NSCLC, and Myeloma, Breakthrough Designation in Prostate Cancer, and More

FDA Approvals in CSCC, NSCLC, and Myeloma, Breakthrough Designation in Prostate Cancer, and More

Gina Columbus reports on FDA approvals in cutaneous squamous cell carcinoma, non–small cell lung cancer, and multiple ...

Advanced CSCC: The New Systemic Therapy

Advanced CSCC: The New Systemic Therapy

Data and practical implications are reviewed from the phase 2 EMPOWER-

Applying the breakthrough therapy criteria: Oncology

Applying the breakthrough therapy criteria: Oncology

... for

Dr. Pazdur on the Requirements for a Breakthrough Therapy Designation

Dr. Pazdur on the Requirements for a Breakthrough Therapy Designation

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and ...

FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More

FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More

George R. Simon, MD, reports on an FDA approval in bladder cancer, a

Immunology Update – October 22, 2025: Etrasimod UC, Upadacitinib Approval, Pediatric SIMPONI & More

Immunology Update – October 22, 2025: Etrasimod UC, Upadacitinib Approval, Pediatric SIMPONI & More

Stay informed with the latest immunology breakthroughs, FDA approvals, and clinical trial updates. In this episode, we highlight ...

FDA Approvals in Large B-Cell Lymphoma and Melanoma, Priority Reviews in CSCC and NSCLC, and More

FDA Approvals in Large B-Cell Lymphoma and Melanoma, Priority Reviews in CSCC and NSCLC, and More

Gina Columbus reports on FDA approvals in large B-cell lymphoma and melanoma, priority review

FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More

FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More

Gina Columbus reports on FDA approvals in graft-versus-host disease, colorectal cancer, and acute myeloid leukemia, a priority ...

Advice for the Management of CSCC

Advice for the Management of CSCC

Key opinion leaders provide some closing thoughts vis-à-vis the

FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More

FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More

Gina Columbus reports on FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, ...

Force Webinar: Phio Pharma, 5 February 2026

Force Webinar: Phio Pharma, 5 February 2026

Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer. Phio's core ...

Optimizing the patient journey in CSCC through multidisciplinary collaboration

Optimizing the patient journey in CSCC through multidisciplinary collaboration

Watch our leading specialists as they discuss the role of the multidisciplinary team in the care of patients with cutaneous ...

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising ...

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising ...

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More

In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising ...

Navigating the Complexities of Step Therapy

Navigating the Complexities of Step Therapy

Navigating the Complexities of Step

Collaborating across disciplines to develop the next cancer breakthrough

Collaborating across disciplines to develop the next cancer breakthrough

At USC Norris Comprehensive Cancer Center, researchers collaborate with top scientists across disciplines and across USC's ...

2026 CCS Exam Prep-Session 9 (Inpatient Prospective Payment System)

2026 CCS Exam Prep-Session 9 (Inpatient Prospective Payment System)

This session introduces the Inpatient Prospective Payment System (IPPS) and explains how inpatient data is used to determine ...

Healing Together: Lessons Learned from Educational Leadership During Disruption

Healing Together: Lessons Learned from Educational Leadership During Disruption

The COVID-19 pandemic created widespread disruptions in clinical care and education. As the pandemic receded, educational ...